Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Aytu Biopharma (AYTU) Net Income towards Common Stockholders: 2009-2025

Historic Net Income towards Common Stockholders for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to $2.0 million.

  • Aytu Biopharma's Net Income towards Common Stockholders rose 415.75% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 195.99%. This contributed to the annual value of $620,000 for FY2025, which is 118.65% up from last year.
  • According to the latest figures from Q3 2025, Aytu Biopharma's Net Income towards Common Stockholders is $2.0 million, which was up 3,069.35% from $62,000 recorded in Q2 2025.
  • In the past 5 years, Aytu Biopharma's Net Income towards Common Stockholders ranged from a high of $2.0 million in Q3 2025 and a low of -$53.3 million during Q1 2022.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$599,000 (2024), whereas its average is -$956,545.
  • Per our database at Business Quant, Aytu Biopharma's Net Income towards Common Stockholders tumbled by 546.80% in 2021 and then soared by 415.75% in 2025.
  • Aytu Biopharma's Net Income towards Common Stockholders (Quarterly) stood at -$11.5 million in 2021, then surged by 42.04% to -$6.7 million in 2022, then surged by 87.46% to -$839,000 in 2023, then soared by 114.66% to $123,000 in 2024, then soared by 415.75% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $62,000 for Q2 2025, and $54,000 during Q1 2025.